Vimarsana
Biggest News Aggregation in the World

Canale Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Canale Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Canale Communications Today - Breaking & Trending Today

Ford Hutman promotes Fuller to managing partner - Vimarsana News

Ford Hutman promotes Fuller to managing partner

Ford Hutman promotes Fuller to managing partner. From PR Week

Source: prweek.com
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome - Vimarsana News

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Ret...

Taysha Gene Therapies Reports Third Quarter 2023 Financial - Vimarsana News

Taysha Gene Therapies Reports Third Quarter 2023 Financial

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of 20-week assessment with...

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Vimarsana News

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome - Vimarsana News

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly e...